Sight Sciences, Inc. (NASDAQ:SGHT) Receives $4.60 Average Target Price from Analysts

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) has earned a consensus rating of "Hold" from the seven analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $4.60.

Separately, Needham & Company LLC reiterated a "hold" rating on shares of Sight Sciences in a research note on Wednesday.

Insider Buying and Selling

In related news, CFO Alison Bauerlein sold 10,123 shares of the stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $5.08, for a total transaction of $51,424.84. Following the sale, the chief financial officer now directly owns 426,248 shares of the company's stock, valued at $2,165,339.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Sight Sciences news, CEO Paul Badawi sold 12,571 shares of the company's stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $5.08, for a total transaction of $63,860.68. Following the completion of the transaction, the chief executive officer now directly owns 5,750,729 shares in the company, valued at $29,213,703.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Alison Bauerlein sold 10,123 shares of the company's stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total transaction of $51,424.84. Following the transaction, the chief financial officer now owns 426,248 shares of the company's stock, valued at $2,165,339.84. The disclosure for this sale can be found here. Over the last three months, insiders have sold 63,441 shares of company stock valued at $324,625. Corporate insiders own 27.10% of the company's stock.

Institutional Investors Weigh In On Sight Sciences

A number of hedge funds have recently modified their holdings of SGHT. US Bancorp DE acquired a new stake in shares of Sight Sciences in the fourth quarter valued at about $27,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Sight Sciences in the third quarter valued at about $37,000. FMR LLC increased its position in Sight Sciences by 484.6% during the second quarter. FMR LLC now owns 4,864 shares of the company's stock worth $44,000 after purchasing an additional 4,032 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in Sight Sciences during the fourth quarter worth about $54,000. Finally, American Century Companies Inc. increased its position in Sight Sciences by 51.0% during the third quarter. American Century Companies Inc. now owns 15,908 shares of the company's stock worth $54,000 after purchasing an additional 5,370 shares during the last quarter. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Sight Sciences Trading Down 2.3 %

Sight Sciences stock traded down $0.14 during trading hours on Wednesday, hitting $5.93. The company had a trading volume of 190,936 shares, compared to its average volume of 233,319. The firm has a market cap of $293.83 million, a P/E ratio of -5.32 and a beta of 2.83. The company has a debt-to-equity ratio of 0.26, a quick ratio of 12.65 and a current ratio of 13.29. Sight Sciences has a 1 year low of $1.04 and a 1 year high of $11.20. The company has a 50-day moving average price of $4.66 and a two-hundred day moving average price of $3.95.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.13. Sight Sciences had a negative net margin of 68.53% and a negative return on equity of 41.94%. The company had revenue of $18.75 million during the quarter, compared to analysts' expectations of $18.70 million. During the same period in the previous year, the company earned ($0.35) EPS. On average, sell-side analysts anticipate that Sight Sciences will post -1.04 earnings per share for the current year.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.